To amend the Families First Coronavirus Response Act to extend child nutrition waiver authority, and for other purposes.

Bill: 117-s-1089
Sponsor: full_name: Sen. Blackburn, Marsha [R-TN]
Introduced: 2021-04-13
Policy area: Health
Subjects: Congressional oversight

Disability and paralysis

Government studies and investigations

Health care costs and insurance

Health care coverage and access

Health care quality

Health information and medical records

Health technology, devices, supplies

Long-term, rehabilitative, and terminal care

Medicare

Performance measurement

Surgery and anesthesia

Veterans' medical care
Latest action: action_date: 2021-04-13
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summaries:
action_date: 2021-04-13
action_desc: Introduced in Senate
text: <p><b>Access to Assistive Technology and Devices for Americans Study Act or the Triple A Study Act</b></p> <p>This bill directs the Government Accountability Office (GAO) to study issues related to health insurance and other coverage for assistive technologies, such as prosthetic devices and custom orthoses, for those who experience amputations or live with a limb difference.</p> <p>In conducting this study, the GAO must include comparisons of claims and other data from Medicare, the Department of Veterans Affairs, and commercial health insurers.</p>

tv_txt: II 117th CONGRESS 1st Session S. 1089 IN THE SENATE OF THE UNITED STATES April 13, 2021 Mrs. Blackburn (for herself and Ms. Duckworth ) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions A BILL To direct the Government Accountability Office to evaluate appropriate coverage of assistive technologies provided to patients who experience amputation or live with limb difference.

1. Short title This Act may be cited as the Access to Assistive Technology and Devices for Americans Study Act or the Triple A Study Act . 2. Appropriate coverage of assistive technologies (a) In general Not later than 18 months after the date of enactment of this Act, the Comptroller General of the United States shall evaluate, and submit to Congress a report on such evaluation, the appropriate coverage, through insurance or otherwise, of assistive technologies provided to patients who experience amputation or live with limb difference, particularly prosthetic devices and custom orthoses, including— (1) timely access to care, including educating patients regarding options for assistive technologies; (2) assessments and guidelines for assistive device determinations; (3) matching specific assistive devices with the needs of the individual beneficiary, such as women, children, and racial and ethnic minorities; (4) the affordability of assistive devices; (5) the provision of rehabilitation services to support acclimation to assistive devices; and (6) appropriate timelines for assessments for surgery and assessments of assistive devices. (b) Comparison of certain data As part of the evaluation conducted under subsection (a), the Comptroller General shall compare data on practices and outcomes derived from the Medicare program under title XVIII of the Social Security Act ( 42 U.S.C. 1395 et seq.), the Department of Veterans Affairs, and the commercial health insurance market relating to the coverage of assistive technologies, including— (1) the percentage of patients who get access to assistive devices; (2) performance measures that monitor the timeliness of processing prosthetic prescriptions; (3) coverage denials and overturn rates; (4) coding for physician or physical therapy or occupational therapy assessments, including whether a prosthetist was engaged in the assessment; (5) the rate of patients returning to work in general, and after receiving a prosthetic device comparable to other assistive technologies; (6) reductions in long-term assistive technology services and supports; (7) with respect to those using assistive technologies, policies to reduce falls and secondary complications, such as diabetes, heart disease, vascular disease, and others; and (8) the amount expended by individual entities on prosthetics relative to total amount expended by such entities.